Filtered By:
Cancer: Cancer
Drug: Methotrexate

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Stroke like syndrome and simple partial seizures secondary to intrathecal methotrexate use for the treatment of acute lymphocytic leukemia. (p6.181)
Conclusions:Our case may be the first reported of seizures and stroke like syndrome in the same patient for ALL treated with MTX. Clinicians should include Methotrexate induced leukoencephalopathy in their differential of seizures, stroke like syndrome and a combination of both. MRI DWI, ADC and FLAIR images should be included in the diagnostic evaluation of MTX induced encephalopathy especially with IT methotrexate.Disclosure: Dr. Fares has nothing to disclose. Dr. Silliman has received research support from Sanofi Genzyme, Biogen Idec, Bristol Myers and Novartis.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Fares, M.-A., Silliman, S. Tags: Neurologic Complications of Cancer Source Type: research

The Incident Ocular Diseases Related to Chemotherapy in Cancer Patients are Associated with Increasing Risk of Incident Stroke
CONCLUSIONS: Incident ocular diseases related to chemotherapy were associated with a significantly higher risk of stroke.PMID:37229341 | PMC:PMC10203719 | DOI:10.6515/ACS.202305_39(3).20221005A
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Kai-Chun Cheng Hung-Pin Tu Tsung-Hsien Lin Kai-Hung Cheng Source Type: research

A Unique Presentation of Pediatric Stroke Attributed to Intrathecal Methotrexate (P3.309)
CONCLUSIONS:This is a rare case of ischemic watershed infarcts with diffuse reversible cerebral vasospasm, after intrathecal methotrexate. This highlights the need for further research into the pathogenesis of methotrexate neurotoxicity including endothelial damage.Study Supported by:Disclosure: Dr. Ilyas has nothing to disclose. Dr. Williams has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ilyas, M., Williams, M. Tags: Neurologic Complications of Cancer Source Type: research

Hacking The Nervous System
(Photo: © Job Boot) One nerve connects your vital organs, sensing and shaping your health. If we learn to control it, the future of medicine will be electric.When Maria Vrind, a former gymnast from Volendam in the Netherlands, found that the only way she could put her socks on in the morning was to lie on her back with her feet in the air, she had to accept that things had reached a crisis point. “I had become so stiff I couldn’t stand up,” she says. “It was a great shock because I’m such an active person.”It was 1993. Vrind was in her late 40s and working two jobs, athletics coach and a carer for disabled ...
Source: Science - The Huffington Post - May 30, 2015 Category: Science Source Type: news

Capecitabine-induced acute toxic leukoencephalopathy.
Abstract A 45-year-old woman was treated by Capecitabine (Xeloda(®)) during 6days for breast cancer with metastatic bone lesions when she presented with nausea, headaches, muscle cramps, dysarthria and swallowing disorders. A stroke was first suspected. Brain CT was normal. MRI showed bilateral and symmetric high signal intensities of deep white matter, corpus callosum and corticospinal tracts on diffusion-weighted imaging and T2 fluid-attenuated inversion recovery (FLAIR) sequence, similar to 5-FU acute leukoencephalopathy. An acute toxic leukoencephalopathy was diagnosed prompting to discontinue capecitabine, w...
Source: Neurotoxicology - May 6, 2017 Category: Neurology Authors: Obadia M, Leclercq D, Wasserman J, Galanaud D, Dormont D, Sahli-Amor M, Psimaras D, Pyatigorskaya N, Law-Ye B Tags: Neurotoxicology Source Type: research

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Conclusions Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E. M., Montecucco, C. M., McInnes, I., Radner, H., Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Osteoporosis, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research

Inflammation modulation and cardiovascular disease prevention
Heart disease and stroke represent the major burden of health worldwide and account for a staggering 17 million deaths yearly. This pandemic is, in great part preventable through simple and modifiable preventive measures such as smoking cessation, healthy eating, regular activity and weight loss. In patients with established atherosclerotic vascular disease, lipid lowering agent have had a major impact on reducing risk, along with pharmacological treatment of elevated blood pressure and the use of anti-thrombotic medication. Despite these advances, there remains a significant residual risk and newer approaches are required...
Source: European Journal of Preventive Cardiology - May 6, 2015 Category: Cardiology Authors: Awan, Z., Genest, J. Tags: Original scientific papers Source Type: research

Jane Cooke Wright (1919-2013): Pioneering oncologist, woman and humanitarian
Jane Wright was a fundamental researcher in cancer chemotherapy in the 1950s–1980s and was one of the first scientists to test anti-cancer drugs on humans rather than solely on mice, discovering the use of the popular antimetabolite drug methotrexate on solid tumours. From her research she was able to conclude which specific anti-cancer agents would have the greatest lethal effect on a patient’s certain cancer type and she invented a method of delivering chemotherapy agents directly to an internal cancer site. During a time when the Civil Rights in the United States of America were undergoing a transformation t...
Source: Journal of Medical Biography - February 12, 2016 Category: History of Medicine Authors: Crosby, H. L. Tags: Original Articles Source Type: research

OS5.8 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG)
We present a retrospective case series of 65 adults with IVL from 14 cancer centers in 6 countries. IVL was restricted to the CNS in 29 cases, with a mean age of 60 years and 91% of patients having neurological deficits at the time of diagnosis. There was a mean diagnostic delay of 20 weeks after presentation of stroke-like symptoms or myelopathy. Ninety-three percent had a poor functional status with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2. Serum LDH was elevated in 87% of patients with no correlation with treatment outcome. Frontline treatment with intravenous high-dose methotrexate-bas...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Zukas, A. M., Bennani, N., Chou, C., Johnston, P., ONeill, B., Nijland, M., Batchelor, T., Nayak, L., Mrugala, M., Schiff, D. Tags: OS5 Glioma: Clinical Source Type: research

Rare-39. intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the primary cns lymphoma collaborative group (ipcg)
We present a retrospective case series of 72 adults with IVL from 16 cancer centers in 6 countries. IVL was present in the CNS in 55 cases, with a mean age of 61.6 years and more than 90% of patients having neurological deficits at the time of diagnosis. There was a mean diagnostic delay of 20 weeks after presentation of stroke-like symptoms or myelopathy. Eighty-five percent had a poor functional status with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2 with another eight percent diagnosed post-mortem. Serum LDH was elevated in 87% of available patients with no correlation with treatment outco...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Zukas, A., Bennani, N., Chou, C., Johnston, P., ONeill, B. P., Nijland, M., Batchelor, T., Nayak, L., Mrugala, M., Low, J., Omuro, A., Ferreri, A., Nishikawa, R., Mishima, K., Fox, C., Wilson, W., Houillier, C., Chamberlain, M., Schiff, D. Tags: RARE TUMORS Source Type: research

Drug Aimed at Inflammation May Lower Risk of Heart Disease and Cancer
A milestone finding for researchers, the connection of inflammatory responses to such illnesses could open the door to new treatments.
Source: NYT Health - August 27, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Brigham and Women's Hospital Lancet, The (Journal) Heart Lung Cancer Smoking and Tobacco Cholesterol Research Preventive Medicine Stroke Immune System Statins (Cholesterol-Lowering Drugs) Clinical Trials Methotrexate (Drug) Ridke Source Type: news

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients.
In conclusion, leukoencephalopathy is well-documented for ALL patients (with a focus on methotrexate), but there is a lack of knowledge for other intravenous chemotherapeutics, other oncological populations, wider age ranges and possible risk factors (e.g. history of CNS event). Furthermore, the long-term neuropsychological impact and potential risk for neurodegenerative processes due to leukoencephalopathy remains inconclusive. Hence, large international databanks, epidemiological and prospective case-control studies are necessary to stratify risk groups for CNS-related side effects. PMID: 32799637 [PubMed - as supplied by publisher]
Source: Journal of Chemotherapy - August 19, 2020 Category: Cancer & Oncology Tags: J Chemother Source Type: research

Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL
Neurotoxicity is a well-documented adverse effect of methotrexate in the treatment of pediatric cancers. The spectrum of symptoms is broad, can include stroke-like episodes and seizures, and classically resolves within days. The majority of patients tolerate subsequent doses without recurrence of symptoms. The population of patients who experience persistent and irreversible neurologic symptoms is poorly described, with the existing literature suggestive of a relationship with radiation therapy. The authors present a case series of 2 patients with pre-B-cell acute lymphoblastic leukemia who developed severe and ultimately ...
Source: Journal of Pediatric Hematology Oncology - October 23, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research